{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T19:26:37Z","timestamp":1759778797478},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,4,7]],"date-time":"2018-04-07T00:00:00Z","timestamp":1523059200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s11936-018-0630-2","type":"journal-article","created":{"date-parts":[[2018,4,7]],"date-time":"2018-04-07T06:19:29Z","timestamp":1523081969000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Technological Advances in Stent Therapies: a Year in Review"],"prefix":"10.1007","volume":"20","author":[{"given":"Jad","family":"Raffoul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammar","family":"Nasir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J. P.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,7]]},"reference":[{"issue":"2","key":"630_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1056\/NEJM197907123010201","volume":"301","author":"AR Gruntzig","year":"1979","unstructured":"Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979;301(2):61\u20138.","journal-title":"N Engl J Med"},{"issue":"9710","key":"630_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0140-6736(09)62127-9","volume":"375","author":"E Kedhi","year":"2010","unstructured":"Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375(9710):201\u20139.","journal-title":"Lancet"},{"issue":"9","key":"630_CR3","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jcin.2015.03.028","volume":"8","author":"PC Smits","year":"2015","unstructured":"Smits PC, Vlachojannis GJ, McFadden E, Royaards KJ, Wassing J, Joesoef KS, et al. Final 5-year follow-up of a randomized controlled trial of Everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice: the COMPARE trial (a trial of Everolimus-eluting stents and paclitaxel stents for coronary revascularization in daily practice). JACC Cardiovasc Interv. 2015;8(9):1157\u201365.","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"630_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jacc.2011.02.023","volume":"58","author":"PC Smits","year":"2011","unstructured":"Smits PC, et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial). J Am Coll Cardiol. 2011;58(1):11\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"9824","key":"630_CR5","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/S0140-6736(12)60324-9","volume":"379","author":"T Palmerini","year":"2012","unstructured":"Palmerini T, Biondi-Zoccai G, Riva DD, Stettler C, Sangiorgi D, D'Ascenzo F, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379(9824):1393\u2013402.","journal-title":"Lancet"},{"issue":"16","key":"630_CR6","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.jacc.2011.02.016","volume":"57","author":"GW Stone","year":"2011","unstructured":"Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a prospective, randomized, multicenter trial to assess an Everolimus-eluting coronary stent system [PROMUS element] for the treatment of up to two de novo coronary artery lesions) trial. J Am Coll Cardiol. 2011;57(16):1700\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"630_CR7","doi-asserted-by":"publisher","first-page":"e002372","DOI":"10.1161\/CIRCINTERVENTIONS.114.002372","volume":"8","author":"DJ Kereiakes","year":"2015","unstructured":"Kereiakes DJ, Meredith IT, Windecker S, Lee Jobe R, Mehta SR, Sarembock IJ, et al. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II randomized trial. Circ Cardiovasc Interv. 2015;8(4):e002372.","journal-title":"Circ Cardiovasc Interv"},{"key":"630_CR8","doi-asserted-by":"crossref","unstructured":"Meredith IT, et al. Final five-year clinical outcomes in the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. EuroIntervention. 2017. Advance online publication. Retrieved from http:\/\/www.pcronline.com\/eurointervention\/ahead_of_print\/JAA_EIJ_EIJ-D-17-00529 . Accessed 11 Nov 2017.","DOI":"10.4244\/EIJ-D-17-00529"},{"issue":"15","key":"630_CR9","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jacc.2011.12.016","volume":"59","author":"IT Meredith","year":"2012","unstructured":"Meredith IT, Verheye S, Dubois CL, Dens J, Fajadet J, Carri\u00e9 D, et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J Am Coll Cardiol. 2012;59(15):1362\u201370.","journal-title":"J Am Coll Cardiol"},{"issue":"10060","key":"630_CR10","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1016\/S0140-6736(16)31920-1","volume":"388","author":"C Birgelen von","year":"2016","unstructured":"von Birgelen C, Kok MM, van der Heijden LC, Danse PW, Schotborgh CE, Scholte M, et al. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. Lancet. 2016;388(10060):2607\u201317.","journal-title":"Lancet"},{"issue":"16","key":"630_CR11","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.4244\/EIJ-D-16-00643","volume":"12","author":"DJ Kereiakes","year":"2017","unstructured":"Kereiakes DJ, et al. Safety and efficacy of a bioabsorbable polymer-coated, everolimus-eluting coronary stent in patients with diabetes: the EVOLVE II diabetes substudy. EuroIntervention. 2017;12(16):1987\u201394.","journal-title":"EuroIntervention"},{"issue":"6","key":"630_CR12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/ccd.27030","volume":"90","author":"G Sarno","year":"2017","unstructured":"Sarno G, Lagerqvist B, Olivecrona G, Varenhorst C, Danielewicz M, Hambraeus K, et al. Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Catheter Cardiovasc Interv. 2017;90(6):881\u20137.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"9915","key":"630_CR13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(13)62037-1","volume":"383","author":"C Birgelen von","year":"2014","unstructured":"von Birgelen C, Sen H, Lam MK, Danse PW, Jessurun GAJ, Hautvast RWM, et al. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. Lancet. 2014;383(9915):413\u201323.","journal-title":"Lancet"},{"issue":"17","key":"630_CR14","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.4244\/EIJ-D-16-00571","volume":"12","author":"LC Heijden van der","year":"2017","unstructured":"\u2022 van der Heijden LC, et al. Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised DUTCH PEERS (TWENTE II) trial. EuroIntervention. 2017;12(17):2128\u201331. This reference is 3-year follow-up data from the DUTCH PEERS trial showing in 1,807 patients (99.8%, four withdrawals) no difference in all-comers randomly assigned 1:1 to treatment with ZES versus EES. The primary endpoint was target vessel failure (TVF) and was a composite of cardiac death, target vessel-related myocardial infarction or target vessel revascularization. There were no differences between the ZES and EES groups with respect to TVF (10.7% vs. 10.3%; pLog-rank=0.77) or any of the subgroups: cardiac death (3.2% vs. 3.1%; pLog-rank=0.87), target vessel-related myocardial infarction (2.8% vs. 2.2%; pLog-rank=0.44) and target vessel revascularisation (6.0% vs. 6.2%; pLog-rank=0.87). In addition, the incidence of definite or probable stent thrombosis was also similar between the two groups for patients treated with ZES (1.4%) versus EES (1.1%; pLog-rank=0.66).","journal-title":"EuroIntervention"},{"issue":"23","key":"630_CR15","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","volume":"371","author":"L Mauri","year":"2014","unstructured":"\u2022 Mauri L, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155\u201366. Landmark trial of >9000 patients showing that extending DAPT beyond 12 months after DES implantation compared to aspirin alone significantly reduced the risks of stent thrombosis,major adverse cardiovascular and cerebrovascular events at the cost of an increased risk of bleeding.","journal-title":"N Engl J Med"},{"issue":"6","key":"630_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1001\/jamacardio.2016.2171","volume":"1","author":"L Mauri","year":"2016","unstructured":"Mauri L, Smith SC Jr. Focused update on duration of dual antiplatelet therapy for patients with coronary artery disease. JAMA Cardiol. 2016;1(6):733\u20134.","journal-title":"JAMA Cardiol"},{"issue":"14","key":"630_CR17","first-page":"1373","volume":"372","author":"L Mauri","year":"2015","unstructured":"Mauri L, Yeh RW, Kereiakes DJ. Duration of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2015;372(14):1373\u20134.","journal-title":"N Engl J Med"},{"issue":"1","key":"630_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.7326\/M16-2389","volume":"167","author":"R Piccolo","year":"2017","unstructured":"Piccolo R, Gargiulo G, Franzone A, Santucci A, Ariotti S, Baldo A, et al. Use of the dual-antiplatelet therapy score to guide treatment duration after percutaneous coronary intervention. Ann Intern Med. 2017;167(1):17\u201325.","journal-title":"Ann Intern Med"},{"issue":"11","key":"630_CR19","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.amjcard.2016.03.005","volume":"117","author":"F D'Ascenzo","year":"2016","unstructured":"D'Ascenzo F, Moretti C, Bianco M, Bernardi A, Taha S, Cerrato E, et al. Meta-analysis of the duration of dual antiplatelet therapy in patients treated with second-generation drug-eluting stents. Am J Cardiol. 2016;117(11):1714\u201323.","journal-title":"Am J Cardiol"},{"key":"630_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f6625","volume":"347","author":"S Bangalore","year":"2013","unstructured":"Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ. 2013;347:f6625.","journal-title":"BMJ"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-018-0630-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-018-0630-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-018-0630-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T16:52:02Z","timestamp":1571071922000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-018-0630-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,7]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["630"],"URL":"https:\/\/doi.org\/10.1007\/s11936-018-0630-2","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,7]]},"assertion":[{"value":"7 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"36"}}